WuXi Biologics (Cayman) Inc. (WXIBF)
USD 1.9
(0.0%)
USD 1.9
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 17.03 Billion | 15.26 Billion | 10.29 Billion | 5.61 Billion | 3.98 Billion | 2.53 Billion |
| Cost of Revenue | 10.2 Billion | 8.54 Billion | 5.46 Billion | 3.07 Billion | 2.32 Billion | 1.51 Billion |
| Gross Profit | 6.82 Billion | 6.72 Billion | 4.82 Billion | 2.53 Billion | 1.65 Billion | 1.01 Billion |
| Operating Expenses | 2.87 Billion | 1.92 Billion | 1.36 Billion | 771.43 Million | 601.77 Million | 323.61 Million |
| Selling, General and Administrative Expenses | 2.08 Billion | 1.43 Billion | 1 Billion | 605.85 Million | 444.36 Million | 270.15 Million |
| Research and Development Expenses | 792.57 Million | 682.81 Million | 501.58 Million | 303.73 Million | 259.65 Million | 169.28 Million |
| Other Expenses | - | 17.94 Million | 837 Thousand | 4.38 Million | -1.97 Million | 2.67 Million |
| Cost and Expenses | 13.08 Billion | 10.47 Billion | 6.82 Billion | 3.85 Billion | 2.92 Billion | 1.84 Billion |
| Operating Income | 3.94 Billion | 6.15 Billion | 3.85 Billion | 1.75 Billion | 1.1 Billion | 876.43 Million |
| Interest Expense | 158.48 Million | 64.38 Million | 39.19 Million | 42.73 Million | 19.6 Million | - |
| Income Tax Expense | 603.17 Million | 807.86 Million | 484.53 Million | 273.06 Million | 116.29 Million | 107.25 Million |
| Earnings before Tax | 4.17 Billion | 5.35 Billion | 3.99 Billion | 1.96 Billion | 1.12 Billion | 737.72 Million |
| Net Income | 3.39 Billion | 4.42 Billion | 3.38 Billion | 1.68 Billion | 1.01 Billion | 630.59 Million |
| Earnings Per Share Basic | 0.77 | 1.06 | 0.81 | 0.43 | 0.27 | 0.16 |
| Earnings Per Share Diluted | 0.78 | 1.01 | 0.77 | 0.40 | 0.25 | 0.16 |
| Weighted Average Shares Outstanding | 4.4 Billion | 4.17 Billion | 4.42 Billion | 4.2 Billion | 3.99 Billion | 3.94 Billion |
| Weighted Average Shares Outstanding (Diluted) | 4.34 Billion | 4.37 Billion | 4.42 Billion | 4.2 Billion | 3.99 Billion | 3.94 Billion |
| Gross Margin | 0.40 | 0.44 | 0.47 | 0.45 | 0.42 | 0.40 |
| EBIT Margin | 0.32 | 0.46 | 0.42 | 0.37 | 0.33 | 0.40 |
| Profit Margin | 0.20 | 0.29 | 0.33 | 0.30 | 0.25 | 0.25 |
| EBITDA | 5.5 Billion | 6.22 Billion | 4.51 Billion | 2.06 Billion | 1.36 Billion | 881.49 Million |
| Earnings Before Tax Margin | 0.23 | 0.40 | 0.37 | 0.31 | 0.28 | 0.35 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 589.9 Million | 593.74 Million | 17.03 Billion | 1.18 Billion | 585 Million | 1.22 Billion |
| Cost of Revenue | 359.43 Million | 361.76 Million | 10.2 Billion | 729.6 Million | 361.24 Million | 711.48 Million |
| Gross Profit | 230.47 Million | 231.97 Million | 6.82 Billion | 451.91 Million | 223.75 Million | 513.71 Million |
| Operating Expenses | 105.28 Million | 105.96 Million | 2.37 Billion | 226.4 Million | 115.53 Million | 181.53 Million |
| Selling, General and Administrative Expenses | 81.61 Million | 82.14 Million | - | 164.94 Million | 80.13 Million | 132.27 Million |
| Research and Development Expenses | 23.67 Million | 23.82 Million | - | 61.46 Million | 30.89 Million | 49.26 Million |
| Other Expenses | - | - | 16.96 Million | - | - | - |
| Cost and Expenses | 464.71 Million | 467.73 Million | 12.58 Billion | 956.01 Million | 476.78 Million | 893.02 Million |
| Operating Income | 125.19 Million | 126 Million | 3.93 Billion | 225.5 Million | 111.65 Million | 332.17 Million |
| Interest Expense | 14.59 Million | - | 158.48 Million | 16.49 Million | - | 16.29 Million |
| Income Tax Expense | 15.69 Million | 15.79 Million | 603.17 Million | 56.99 Million | 28.21 Million | 27.57 Million |
| Earnings before Tax | 138.17 Million | 139.07 Million | 4.17 Billion | 227.5 Million | 112.64 Million | 364.86 Million |
| Net Income | 103.13 Million | 103.8 Million | 3.39 Billion | 156.71 Million | 77.59 Million | 327.02 Million |
| Earnings Per Share Basic | 0.02 | 0.02 | - | 0.04 | 0.02 | 0.08 |
| Earnings Per Share Diluted | 0.02 | 0.02 | - | 0.03 | 0.02 | 0.08 |
| Weighted Average Shares Outstanding | 4.3 Billion | 4.3 Billion | 4.16 Billion | 4.25 Billion | 4.48 Billion | 4.15 Billion |
| Weighted Average Shares Outstanding (Diluted) | 4.25 Billion | 4.25 Billion | 4.34 Billion | 4.34 Billion | 4.34 Billion | 4.34 Billion |
| Gross Margin | 0.39 | 0.39 | 0.40 | 0.38 | 0.38 | 0.42 |
| EBIT Margin | 0.29 | 0.29 | - | 0.27 | 0.23 | 0.35 |
| Profit Margin | 0.17 | 0.17 | 0.20 | 0.13 | 0.13 | 0.27 |
| EBITDA | 170.14 Million | 171.24 Million | - | 324.7 Million | 136.26 Million | 428.62 Million |
| Earnings Before Tax Margin | 0.21 | 0.21 | 0.23 | 0.19 | 0.19 | 0.27 |
JLHL
1033
002926
7867
300735
600822